← Back to Search

Polyphenols

Resveratrol, Quercetin, Curcumin (RQC) for Age-Related Macular Degeneration

Phase 2
Waitlist Available
Led By Paul A Knepper, MD, PhD
Research Sponsored by Paul A Knepper, MD PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial looks at whether a combination of resveratrol, quercetin, and curcumin is safe and effective in treating age-related macular degeneration.

Eligible Conditions
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events
Change in Drusen Volume from Baseline
Geographic Atrophy (GA) Growth Rate
+1 more
Secondary outcome measures
Progression to Advanced AMD

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Resveratrol, Quercetin, Curcumin (RQC)Experimental Treatment1 Intervention
Resveratrol (100mg BID), Quercetin (120mg BID), Curcumin (1000mg BID); 24 months
Group II: CurcuminActive Control1 Intervention
Curcumin (1000mg BID); 24 months

Find a Location

Who is running the clinical trial?

Paul A Knepper, MD PhDLead Sponsor
Paul A Knepper, MD, PhDPrincipal InvestigatorZaparackas Knepper, Ltd
Zibute Zaparackas, MDPrincipal InvestigatorZaparackas Knepper, Ltd

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people total have signed up for this experiment?

"Yes, you are correct. The clinical trial is currently admitting 150 participants between 1 locations."

Answered by AI

Does this research opportunity extend to elderly patients?

"This trial is for patients aged 50-90, with 14 other trials existing for people younger and 190 for senior citizens."

Answered by AI

Who does this clinical trial hope to include in its research?

"Eligible participants for this clinical research must have macular degeneration and be between the ages of 50-90. A total of 150 people will be accepted into the study."

Answered by AI

Are RQC supplements effective in treating other illnesses?

"To date, there are 31 active clinical trials studying the effects of Resveratrol, Quercetin, Curcumin (RQC). 4 of these studies have progressed to Phase 3. There is a global distribution of trial sites for RQC, with 35 different locations running independent investigations."

Answered by AI

Could you please go over the possible side effects of taking RQC?

"Because there is only evidence of safety and no efficacy data in human trials, our team at Power has given RQC a score of 2."

Answered by AI

Can new people still join this clinical trial?

"The study, which was first posted on 7/22/2021, is looking for more participants and was last updated 9/20/2021 according to clinicaltrials.gov"

Answered by AI

Who else is applying?

What state do they live in?
Indiana
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
Archives of OphthalmologyJournal
The Age-related Eye Disease Study Severity Scale for Age-related Macular Degeneration
“The Age-related Eye Disease Study Severity Scale for Age-related Macular Degeneration”. 2005. “The Age-related Eye Disease Study Severity Scale for Age-related Macular Degeneration”. Archives of Ophthalmology. American Medical Association (AMA). doi:10.1001/archopht.123.11.1484.
Cancer Epidemiology, Biomarkers & PreventionJournal
Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent
Boocock, David J., Guy E.S. Faust, Ketan R. Patel, Anna M. Schinas, Victoria A. Brown, Murray P. Ducharme, Tristan D. Booth, et al.. 2007. “Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent”. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR). doi:10.1158/1055-9965.epi-07-0022.
Clinical Cancer ResearchJournal
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Dhillon, Navneet, Bharat B. Aggarwal, Robert A. Newman, Robert A. Wolff, Ajaikumar B. Kunnumakkara, James L. Abbruzzese, Chaan S. Ng, Vladimir Badmaev, and Razelle Kurzrock. 2008. “Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer”. Clinical Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/1078-0432.ccr-08-0024.
Journal of Leukocyte BiologyJournal
MD-2 as the Target of Curcumin in the Inhibition of Response to LPS
Gradišar, Helena, Mateja Manček Keber, Primož Pristovšek, and Roman Jerala. 2007. “MD-2 as the Target of Curcumin in the Inhibition of Response to LPS”. Journal of Leukocyte Biology. Wiley. doi:10.1189/jlb.1206727.
~40 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top